BioSpace News Archive

BioSpace recently spoke with James Oliviero, CEO and president at Checkpoint Therapeutics, an immuno-oncology, late-stage development company.

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

Revolution Medicines, Inc., a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, announced its financial results for the second quarter and six months ended June 30, 2021, and provided a corporate update.

Heat Biologics, Inc., a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, provided financial, clinical and operational updates for the second quarter ended June 30, 2021.

GBS Inc., a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point-of-care, announced its financial results for the fourth financial quarter and full-year ended June 30, 2021, and provided a recent business update.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, presented the Omnipod DASH® Insulin Management System to healthcare providers attending the virtual Australasian Diabetes Congress.

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced additional data from the EQUALISE Type A portion of the study in systemic lupus erythematosus (SLE) patients.

Navidea Biopharmaceuticals, Inc. today announced its financial results for the second quarter and year-to-date for the period ended June 30, 2021.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the second quarter ended June 30, 2021.

Conference call to discuss financial and operational results scheduled for Thursday, August 12, at 8:00 a.m. U.S. Eastern Time